Verona Pharma VRNA
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Verona Pharma (VRNA) Business Model and Operations Summary
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Key Insights
Verona Pharma (VRNA) Core Market Data and Business Metrics
Latest Closing Price
$105.28Market Cap
$5.54 BillionAverage Daily Volume
1,378,874 Shares52-Week Range
$11.39-$70.40Total Outstanding Shares
85.13 Million SharesCEO
Dr. David S. Zaccardelli Pharm.D.Total Employees
209Current Dividend
No dividendIPO Date
April 27, 2017SIC Description
Pharmaceutical PreparationsHeadquarters
3 More London Riverside, London, X0, SE1 2RE